Skip to main content
Ventripoint Diagnostics Ltd. logo

Ventripoint Diagnostics Ltd. — Investor Relations & Filings

Ticker · VPT LEI · 529900QV0P93LL6P2M57 TSXV Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 256 across all filing types
Latest filing 2025-01-30 Board/Management Inform…
Country CA Canada
Listing TSXV VPT

About Ventripoint Diagnostics Ltd.

https://ventripoint.com/

Ventripoint Diagnostics Ltd. is a medical device company specializing in AI-driven cardiac imaging solutions. The company's patented technology, embodied in the VMS+ software, transforms standard 2D echocardiograms into high-fidelity 3D models of all four heart chambers. This process provides accurate, reproducible volumetric measurements and ejection fractions, offering diagnostic performance comparable to MRI but with the speed and cost-effectiveness of ultrasound. The VMS+ system is designed to aid in monitoring patients with heart conditions, delivering detailed heart analysis even when using imperfect images or on patients who cannot undergo MRI procedures, such as those with pacemakers.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the addition of Karl Pringle to the company’s Business Advisory Board to bolster its sales strategy. This is a management appointment announcement, which falls under Board/Management Information (MANG).
2025-01-30 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing an update to Ventripoint’s submission of its VMS+ 4.0 technology to the FDA. It contains product/regulatory news, quotes from executives, and forward‐looking statements but does not constitute a financial report, shareholder meeting material, or an SEC/SEDAR filing of financial results. It is a general regulatory announcement (miscellaneous press release) and fits the fallback category “Regulatory Filings (RNS).”
2025-01-21 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian NI 51-102 Material Change Report (Form 51-102F3) detailing the closing of the second tranche of a non-brokered convertible debenture private placement, terms of the debentures, use of proceeds, related-party details, and extension of the offering. This is an update on the company’s fundraising/financing activities. It is not an earnings release, management discussion, or annual report but specifically a financing update. Therefore it fits the Capital/Financing Update category.
2025-01-20 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release by Ventripoint Diagnostics announcing the closing of the second tranche of a non-brokered private placement of convertible debentures and the extension of the offering. It provides detailed terms of the financing, interest, conversion mechanics, insider participation, and use of proceeds. This clearly falls under updates on company fundraising and capital structure changes, matching the “Capital/Financing Update” category.
2025-01-20 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the issuance of common shares by Ventripoint Diagnostics Ltd. to satisfy debenture interest payments, which constitutes a change in the company’s capital structure through new share issuance. This fits the 'Share Issue/Capital Change' category (SHA).
2025-01-10 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is Form 45-106F1 “Report of Exempt Distribution,” which is a Canadian securities regulatory compliance filing reporting details of a prospectus-exempt distribution. It is not an annual or interim report, earnings release, investor presentation, or any M&A/financing announcement in a marketing sense. It does not announce board changes, dividends, or governance policies, nor is it a transaction in own shares. It is a regulatory compliance form that doesn’t fit other specific categories, making it a general regulatory filing (RNS).
2024-12-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.